WO2021123925A1 - Compositions à base d'herbes et procédés d'administration servant au traitement d'infections et d'inflammation vulvovaginale et des organes pelviens - Google Patents

Compositions à base d'herbes et procédés d'administration servant au traitement d'infections et d'inflammation vulvovaginale et des organes pelviens Download PDF

Info

Publication number
WO2021123925A1
WO2021123925A1 PCT/IB2020/055399 IB2020055399W WO2021123925A1 WO 2021123925 A1 WO2021123925 A1 WO 2021123925A1 IB 2020055399 W IB2020055399 W IB 2020055399W WO 2021123925 A1 WO2021123925 A1 WO 2021123925A1
Authority
WO
WIPO (PCT)
Prior art keywords
herbal
disinfecting composition
content
species
present disclosure
Prior art date
Application number
PCT/IB2020/055399
Other languages
English (en)
Inventor
Maryam KHAZAEI SANI
Original Assignee
Banooye Armaghan Teb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banooye Armaghan Teb filed Critical Banooye Armaghan Teb
Priority to DE112020006124.8T priority Critical patent/DE112020006124T5/de
Priority to CN202080087372.6A priority patent/CN115066250A/zh
Publication of WO2021123925A1 publication Critical patent/WO2021123925A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)

Definitions

  • This application is related to herbal compositions and administration methods for vulvovaginal infection treatment, reviving normal flora of vulvovaginal area, treatment of diseases related to the vagina, or preventing pelvic organ infections or inflammations.
  • Vulvovaginal infections are infections related to the lower parts of the genitalia that affect the vagina and vulva. These infections commonly exhibit their effects by itching, discomfort, pain, and unusual vaginal discharges. Vulvovaginal infections majorly have bacterial or fungal origins. The infections originated from the presence of protozoa, majorly trichomonas, comprise only 10% of these infections. The bacterial infections comprise about 50-60% of all vulvovaginal infections. The most common microorganisms observed in this type of infection include Gardnerella vaginalis, Gardnerella mobiluncus, Chlamydia trachomatis, Mycoplasma hominis, Peptostreptococcus, or Ureaplasma urealyticum.
  • the available chemical treatments for vulvovaginal infections and other pelvic organ diseases of women are commonly dissatisfactory and lead to different side effects such as recurrence of the diseases, causing the medical resistance, disturbing the balance in the normal flora, and occurrence of discomfort in other organs such as the stomach, intestine, and liver due to the systemic absorption of the drug.
  • studies on active agents comprising natural or herbal medicine can be a suitable solution for this problem.
  • the present disclosure is directed to an exemplary method for treatment of a disease related to the vagina, preventing a vulvovaginal, reviving a normal flora of a vulvovaginal area, or preventing other organ infections or inflammations in a subject.
  • the method may include applying an effective amount of an herbal disinfecting composition to the subject, wherein the herbal disinfecting composition may comprise of at least one or more plants from the Citrullus colocynthis genus, Commiphora myrrha genus, Myrtus communis genus, or Rosa damascene or a mixture of these plants.
  • the herbal disinfecting composition may include Citrullus colocynthis species with a 30-50 wt% content, Commiphora myrrha species with a 20-50 wt% content, Myrtus communis species with a 30-50 wt% content, and Rosa damascene species with a 20-50 wt% content in the final composition.
  • the herbal disinfecting composition may be in a form of a powder, a granule, or a micro-granule.
  • applying the effective amount of the herbal disinfecting composition may include administration of the effective amount of a vaginal form of the herbal disinfecting composition inside a vagina or a part of vagina of the subject.
  • the vaginal form may include a fibrous pack.
  • the subject may be a human.
  • preventing vulvovaginal may include preventing or stopping the growth of at least one of the microorganisms, wherein the microorganisms may include Trichomonas vaginalis, Candida albicans, Gardnerella vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, or herpes simplex virus.
  • the disease related to the vagina may include vaginitis, vaginal discharge, gonorrhea, bacterial vaginosis, sexually transmitted disease, atrophic vaginitis, fungal infection, or genital warts.
  • the effective amount of the herbal disinfecting composition may be at least one course including at least once a day for at least 14 days
  • the present disclosure is directed to an herbal disinfecting composition.
  • the herbal disinfecting composition may include Citrullus colocynthis, Commiphora myrrha, Myrtus communis, and Rosa damascene.
  • the herbal disinfecting composition may include Citrullus colocynthis species with a 30-50 wt% content, Commiphora myrrha species with a 20-50 wt% content, Myrtus communis species with a 30-50 wt% content, and Rosa damascene species with a 20-50 wt% content in the final composition.
  • the herbal disinfecting composition may include a fruit of Citrullus colocynthis, at least one or a mixture of a flower, a bud, a petal, or a stem of Rosa damascene, at least one or a mixture of a leave, a fruit, or a gum of Commiphora myrrha, and at least one or a mixture of a leave or a fruit of Myrtus communis plants.
  • the herbal disinfecting composition may further comprise a drug carrier including a liquid or a solid filler, a stabilizer, a dispersing agent, a suspending agent, a diluting agent, an excipient, a consolidating agent, a solvent, or an entrapping agent.
  • the present disclosure is directed to a fibrous pack for administrating an herbal medicine.
  • the fibrous pack may include a cylindrical body, a string with two ends, wherein the string may be connected to the cylindrical body from one end, and a middle section, wherein the middle section may be configured to hold the herbal medicine.
  • the herbal medicine may comprise a mixture of dried plants including plants of Citrullus colocynthis species with a 30-50 wt% content, Commiphora myrrha species with a 20-50 wt% content, Myrtus communis species with a 30-50 wt% content, and Rosa damascene species with a 20-50 wt% content in the final medicine.
  • the herbal medicine may be in a form of a powder, a plurality of granules, or a plurality of micro-granules.
  • the cylindrical body may comprise of a nonwoven or a woven as single-ply or multi-ply fiber.
  • the cylindrical body may be the woven fiber in a simple, a non-fuzzy, a low-fuzz, or a high-fuzz form.
  • the cylindrical body may be in a shape including a conical, a cylindrical, a spherocylinder, a circle, a pearl, a bullet, or a teardrop.
  • the fibrous pack may further comprise an applicator, wherein the applicator may include a holder and a handle, wherein the cylindrical body may be placed inside the holder.
  • FIG. 1 illustrates a schematic view of an applicator from the side view, consistent with one or more exemplary embodiments of the present disclosure.
  • FIG. 1 illustrates a schematic view of the applicator from the top view, consistent with one or more exemplary embodiments of the present disclosure.
  • FIG. 1 illustrates a schematic view of a fibrous pack from the side view, consistent with one or more exemplary embodiments of the present disclosure.
  • FIG. 1 illustrates a schematic view of the fibrous pack from the front view, consistent with one or more exemplary embodiments of the present disclosure.
  • FIG. 1 illustrates a plot of the herbal disinfecting composition release for four types of the fibrous packs, including the simple weave, vertical weave, low-fuzz weave, and high-fuzz weave, consistent with one or more exemplary embodiments of the present disclosure.
  • FIG. 1 illustrates microscope images of histological investigations on the tissue samples prepared from the vagina of control rabbits treated by the fibrous pack without the herbal disinfecting composition (a, b, and c) and rabbits treated by the fibrous pack comprising the herbal disinfecting composition as inside-vagina (d, e, and f), consistent with one or more exemplary embodiments of the present disclosure.
  • the term “disinfecting” or “disinfector” can imply different meanings including antibiotic, antiseptic, antifungal, antibacterial, antiprotozoal, and antivirus properties and or other words with the same concept. These definitions do not only comprise the said instances.
  • the concepts “antifungal”, “antibacterial”, “antiprotozoal”, or similar terms used in the present disclosure imply the prevention of growth, stopping the population growth of fungi, bacteria, protozoa, or viruses, or decrease in the intensity or the probability of the development of a fungal, bacterial, protozoal, or virus disease. These concepts can also be defined as the death of fungi, bacteria, or protozoa or decrease or inhibiting the pathogenic effects of those fungi, bacteria, or protozoal.
  • the terms bactericide and fungicide can be used instead of the terms antibacterial and antifungal, respectively.
  • the herbal disinfecting composition is of antimicrobial properties.
  • antimicrobial in the present disclosure implies being effective in preventing, inhibiting, or stopping the growth or the pathogenic effects of a microorganism. Microorganism here implies any type of bacterium, virus, fungus, or protozoon.
  • the term “subject” of the herein disclosed methods may include mammals.
  • the subject implies human.
  • the composition disclosed in this application can be used for human subjects with male or female sexuality or for treating infections and inflammations in women or men.
  • plants of the herein disclosed method may include Citrullus colocynthis species, Commiphora myrrha species, Myrtus communis species, or Rosa damascene species.
  • the term “effective amount” or “effective dose“ of the herein discloser implies an amount that is enough for the desirable or suitable antimicrobial or generally the disinfecting activity includes, but is not limited to, killing microorganisms or inhibiting the microbial infection, inhibiting the growth or toxicity as well.
  • the concept of “effective amount” implies the amount that is required for decreasing or improving at least one of the signs of diseases compared to an untreated patient.
  • the effective amount of an active agent used for medicinal treatment of a disease is different depending on the administration method, extent of disease, stage of the disease, age, sex, body weight, and the general health condition of the subject.
  • the effort was made to treat fungal, bacterial, virus and protozoal infections of vulvovaginal and other pelvic organs including uterus, vulva, and cervix using a new composition of medicinal herbs chosen from the genera including Citrullus genus, Commiphora genus, Rosa genus, and Myrtus genus using given proportions, and using a suitable carrier to deliver the drug topically to the mucus tissue of the vagina.
  • the present disclosure also causes the excretion of infections of the depth of the vagina, uterus, and pelvic organs by diluting them. Hence the present disclosure causes the complete excretion of the infectious and odorous discharges from the vulvovaginal region and, therefore, the complete purge of this region besides treating the infection.
  • the present disclosure presents an herbal composition with disinfecting property.
  • the herbal disinfecting composition may include at least one or more plants from genera including Citrullus genus with 10-90 wt% content, Commiphora genus with 10-90 wt% content, Myrtus genus with 10-90 wt% content, and Rosa genus with 10-90 wt% content (in the final composition) or a mixture of these plants.
  • the herbal disinfecting composition may include at least one or more plants from genera including Citrullus genus with 30-50 wt% content, Commiphora genus with 20-50 wt% content, Myrtus genus with 30-50 wt% content, and Rosa genus with 20-50 wt% content (in the final composition) or a mixture of these plants.
  • Citrullus genus includes the colocynth species with the scientific name Citrullus colocynthis, from the cucurbitaceae family that grows naturally in dry regions. This big plant runner may have hairy leaves, solitary yellow flowers, and round green and white fruits that may turn to yellow when ripe. This plant commonly grows in countries such as Saudi Arabia, Iran, Jordan, Egypt, Iran, India, and Pakistan and is known with names such as colocynth, bitter apple, bitter cucumber, desert gourd, egusi, vine of Sodom, wild gourd, and in the south of Iran it is known as Caspian. The name of the plant used in the present disclosure is not limited only to the said names.
  • Commiphora genus includes Mur Makki species with the scientific name of Commiphora myrrha and other species of Commiphora. This plant is also known by names African myrrh, herabol myrrh, Somali myrrhor, common myrrh, or gum myrrh. The name of the plant used in the present disclosure is not limited only to the said names.
  • Commiphora genus can include other species of this genus, including Commiphora abyssinica, Commiphora schimperi, Commiphora erythraea, and Commiphora molmol as well. The used plant of this genus is not limited only to said instances.
  • myrtus genus includes the myrtle species with the scientific name Myrtus communis, belongs to the Myrtaceae family. This plant is also known as “common myrtle”. This plant is a shrub and can grow up to 2-3 m from the ground. The stems of this shrub can grow irregularly and may be covered by a fawn-colored dermal tissue. The leaves of this plant may be green, stiff, and dark green colored.
  • the name of the plant used in the present disclosure is not limited only to the said instances.
  • Rosa genus includes the red rose with the scientific name Rosa damascene. This plant is also known with other names such as rose, Damask rose, rose hybrid, Rosa gallica, Rosa moschata, and Rosa fedtschenkoana. The name of the plant used in the present disclosure is not limited only to the said instances.
  • the herbal disinfecting composition of the present disclosure may be used for prevention or stopping the growth of at least one of the following microorganisms.
  • microorganisms may include Trichomonas vaginalis, Candida albicans, Gardnerella vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae (GNCO), or herpes simplex virus.
  • the herbal disinfecting composition presented in this disclosure may be used for treating diseases related to the vagina, for example, but not limited to, vaginitis, vaginal discharge, gonorrhea, bacterial vaginosis, sexually transmitted diseases, atrophic vaginitis, fungal infection, genital warts.
  • the herbal disinfecting composition with the disinfecting property may comprise one or more plants of the Citrullus colocynthis species with 30-50 wt% content, Commiphora myrrha species with 20-50 wt% content, Myrtus communis species with 30-50 wt% content, and Rosa damascene species with 20-50 wt% (in the final composition) or a mixture of these species.
  • the herbal disinfecting composition can comprise one or more of the following: water-soluble extracts of one or more plants, a powder comprising at least one or more dried plants, oil-soluble extracts of at least one or more plants, powder of one or more plants prepared using spray-drying, powder of the extracts in which the protein of irons is hydrolyzed that can include the extracts of one or more plants, essential oil of one or more plants, active agents of one or more plants, powder of pomace or the flesh of peeled fruit of one or more plants, extracts of one or more plants capsulated in liposome and/or extracts of one or more plants encapsulated in a polymer.
  • one or more of dried plants including Citrullus colocynthis, Commiphora myrrha, Myrtus communis, or Rosa damascene can be prepared as a powder. Hence in this embodiment, different parts of these plants can be grinded.
  • the herbal disinfecting composition different parts of plants including at least one or a mixture of fruits, leaves, stems, roots, flowers, buds, petals, dermal tissue, gum, resin, or a mixture of them may be used.
  • fruits of colocynth may be used.
  • At least one or a mixture of flowers, buds, petals, or stems of damask rose may be used.
  • At least one or a mixture of leaves or fruits of Myrtus plants may be used.
  • At least one or a mixture of leaves, fruits, or the gum of Myrrha plant may be used.
  • using the herbal composition presented in this disclosure may limit the possibility of recurrence of disease and recurrent infection, which happens due to the imbalance in the saprophytic flora.
  • the developed method for administering this composition not only treats the infection but also purges the environment of the vagina and the excretion of discharges, infections, and drug residues from the vaginal area.
  • One of the embodiments of the present disclosure is related to the production of the herbal disinfecting composition in the vaginal form and dosage including vaginal ointment, vaginal cream, vaginal gel, vaginal liquid, vaginal emulsion, vaginal suspension, vaginal foam, tampon, vaginal pill, vaginal capsule, vaginal ring, lotion, ovule, vaginal douche, powder, granule, micro-granule, aerosol, film, drop, spray, fibrous pack, and suppository.
  • vaginal ointment vaginal cream, vaginal gel, vaginal liquid, vaginal emulsion, vaginal suspension, vaginal foam, tampon, vaginal pill, vaginal capsule, vaginal ring, lotion, ovule, vaginal douche, powder, granule, micro-granule, aerosol, film, drop, spray, fibrous pack, and suppository.
  • preparing the herbal disinfecting composition may comprise of preparing a powder mixed from dried plants, including Citrullus colocynthis, Commiphora myrrha, Myrtus communis, and Rosa damascene.
  • preparing the herbal disinfecting composition may comprise of preparing a granule, a micro-granule, a plurality of granules, or a plurality of micro-granules, including a powder mixed from dried plants including Citrullus colocynthis, Commiphora myrrha, Myrtus communis, and Rosa damascene.
  • the powder mixed from the dried plants and/or granules or micro-granules including Citrullus colocynthis, Commiphora myrrha, Myrtus communis, and Rosa damascene may be administered to the subject using a fibrous pack.
  • one acceptable drug carrier in order to prepare the herbal disinfecting composition, one acceptable drug carrier may be used.
  • the suitable drug carrier implies any type of acceptable drug material including liquid or solid fillers, stabilizers, dispersing agents, suspending agents, diluting agents, excipients, consolidating agents, solvents or entrapping agents that have application in carrying or transporting the composition or molecule used in the present disclosure to the body of the subjects so that the composition or the molecule can carry out the expected activity.
  • the carrier may include any kind of coating agent, antibacterial or antifungal agent, and drug absorption moderator agents, and similar instances that need to be compatible with the activity of the herbal disinfecting composition of the present disclosure and be acceptable for the subject physiologically.
  • the herbal disinfecting composition of the present disclosure can be administered on different surfaces of the body, skin, a bodily cavity, or a mucosal surface, for instance, nose, mouth, eye, ears, respiratory system, vagina or rectum. Also, in some embodiments, the present disclosure can be applied in different forms of administration to the subject.
  • the treatment method and/or the method of preventing vulvovaginal or other pelvic organ infections and/or inflammations and/or reviving the normal flora of the vulvovaginal area in the intended subject as well may include applying the “effective amount” of the herbal disinfecting composition to the subject.
  • the herbal disinfecting composition may include at least one or more dried plants from genera including Citrullus genus with 10-90 wt% content, Commiphora genus with 10-90 wt% content, Myrtus genus with 10-90 wt% content, and Rosa genus with 10-90 wt% content (in the final composition) or a mixture of these plants.
  • the herbal disinfecting composition may comprise at least one or more dried plants from the Citrullus colocynthis genus with 30-50 wt% content, Commiphora myrrha genus with 20-50 wt% content, Myrtus communis genus with 30-50 wt% content, and Rosa damascene with 20-50 wt% content (in the final composition) or a mixture of these genera.
  • the herbal disinfecting composition may be administered through the vagina.
  • the effective amount or effective dose for treatment method using the herbal disinfecting composition can be 0.5 to 10 gr.
  • the effective dose for treatment method using the herbal disinfecting composition can be daily, particularly at least once a day for 10-24 hours, and more particularly at least once a day for 15-24 hours.
  • treating vaginitis may include using the herbal disinfecting composition, at least once a day and for at least 4 days, particularly for at least 7 days, and more particularly for at least 14 days.
  • treating chronic infections and/or inflammations and/or diseases related to the pelvic organs can comprise using the herbal disinfecting composition at least once a day for at least 14 days, here called a course, and particularly for at least one course or several courses during 6-8 months and/or longer until obtaining favorable results.
  • the effective dose for preventing vulvovaginal or other pelvic organ infections and/or inflammations and/or reviving the normal flora of the vulvovaginal area can be daily, particularly at least once a day for 10-24 hours, and more particularly at least once a day for 15-24 hours, for less than 4 days.
  • the effective dose of the herbal disinfecting composition administered to the subject is depended on the route of administration and in powder form is related to particle size. In one or more embodiments of the present disclosure, the effective amount of the herbal disinfecting composition administered to the subject can be in the range of 0.5 to 10 gr, particularly in the range of 2 to 7 gr.
  • the herbal disinfecting composition can be administered to the patient using doses and periods that are effective for treating the disease or disturbing or decreasing the signs of the intended disease in the present disclosure.
  • the effective dose of the herbal disinfecting composition that is required for obtaining the treatment effects can be determined according to factors such the type, extent and stage of the disease or disorder in the patient, age, body weight and sex of patient.
  • the dose can be regulated to obtain the optimum treatment response. For instance, the dose can gradually decrease.
  • the dosage is divided into several doses or can be administered as daily or special time sequences by decreasing the doses during the time.
  • the herbal disinfecting composition can also comprise at least one of the following drugs or compositions or a mixture of them.
  • these instances include all antifungal agents, antibacterial agents, antimicrobial agents, antivirus agents, anti-infectives, spermicides, hormones, antibiotics, analgesics, anti-trichomonas agents, antiprotozoal agents, anti-mycoplasma agents, anti-retrovirus agents, nucleoside analogues, reverse telomerase enzyme (reverse transcriptase), protease inhibitors, anti-fertility agents, steroids, antiemetic agents, dyes, fragrance agents, antihistamines, anti-inflammatory agents, antineoplastics, antioxidants, vitamins, drug absorption promoters, inorganic substances, and herbal extracts with the goal of administration inside the vagina.
  • drugs and compositions are not only limited to said instances.
  • a drug or medical product comprising the herbal disinfecting composition can be administered to a goal spot or goal area, specifically vagina.
  • This drug or medical product comprising the herbal disinfecting composition can be of properties such as disinfecting properties for example, but not limited to, antifungal, antibacterial antiprotozoal, and antivirus properties and also properties including cleaning, pH-regulation, preventing the disease from becoming chronic, the recurrence of the disease or infection, and preventing the imbalance in the normal flora.
  • the kit can control the drug release and undesirable symptoms in high doses or direct administration of the herbal medicine.
  • the kit may comprise of an applicator for easily placing the fibrous pack inside the vagina by the user.
  • the applicator may comprise of a holder 101 and a handle 103 itself.
  • a cylindrical body 301 can be placed inside the holder 101 and then placed inside the vagina with the aid of the handle 103 .
  • the kit may comprise the fibrous pack for administration inside the vagina.
  • the fibrous pack may comprise the cylindrical body 301 that itself may include: 1) the herbal disinfecting composition, including a plurality of herbal compositions and 2) a string with two ends including a first end 303 and a second end 307 , wherein the string may be connected to the cylindrical body 301 from the first end 303 .
  • the cylindrical body 301 may comprise a middle section, wherein the middle section may comprise the herbal medicine, for example, but not limited to, Nigella sativa, Plantago major, Descurainia Sophia, Chamomile, Alcea Citrullus colocynthis, Commiphora myrrha, Myrtus communis, and Rosa damascene genus.
  • the herbal medicine for example, but not limited to, Nigella sativa, Plantago major, Descurainia Sophia, Chamomile, Alcea Citrullus colocynthis, Commiphora myrrha, Myrtus communis, and Rosa damascene genus.
  • the middle section may comprise the herbal disinfecting composition including a mixture of dried plants and particularly in the powder form including plants of Citrullus colocynthis species with a 30-50 wt% content, Commiphora myrrha species with a 20-50 wt% content, Myrtus communis species with a 30-50 wt% content, and Rosa damascene species with a 20-50 wt% content in the final composition.
  • the cylindrical body 301 may include a plurality of granules or micro-granules of herbal disinfecting composition including plants of Citrullus colocynthis species with a 30-50 wt% content, Commiphora myrrha species with a 20-50 wt% content, Myrtus communis species with a 30-50 wt% content, and Rosa damascene species with a 20-50 wt% content so that the ratios or composition of these plants is based on the final weight of the granules or micro-granules.
  • the cylindrical body 301 may compose of fibers or nanofibers made of animal-based material such as silk or wool, plant-based materials such as cotton, synthetic materials, such as polyester, absorbable material, or a mixture of these materials, so that this body may have a diameter between 0.1-2.5 cm and length of 3-10 cm and can be nonwoven or woven as single-ply or multi-ply particularly including 3-6ply.
  • the length of the cylindrical body 301 can be between 5-10 cm.
  • the string that is connected to the cylindrical body 301 by the first end 303 in one or more embodiments of the present disclosure, can be of a length between 5-15 cm.
  • the cylindrical body 301 can be prepared as different shapes, for example, but not limited to, conical, cylindrical, spherocylinder, circle, pearl, bullet, and teardrop shapes and in different sizes.
  • the shapes and sizes of the cylindrical body 301 are not limited to only said instances.
  • a plurality of granules or micro-granules composed of drugs, the herbal disinfecting compositions, or the herbal medicine may be located at the center of the cylindrical body 301 .
  • the cylindrical body 301 can be prepared from fibers, so that generally the herbal medicine, the herbal disinfecting composition, or drugs, for instance, in form of granules or micro-granules can be located in between the fibers in the cylindrical body 301 .
  • these fibers may comprise of the herbal medicine or the herbal disinfecting composition.
  • this cylindrical body 301 may comprise a tampon including the herbal medicine or the herbal disinfecting composition, so that this tampon may be located inside the cylindrical body 301 or at its center.
  • these fibers can be in woven annular form and comprising of cotton fibers.
  • these fibers can be woven in annular, horizontal, or vertical forms.
  • these fibers can be nonwoven or woven in simple, non-fuzzy, low-fuzz, or high-fuzz forms.
  • the fibrous pack of the present disclosure can be applied on different surfaces of the subject body, skin, mucosal surface, for instance, nose, mouth, ears, respiratory system, different canals of the subject body, Pudendal canal, vagina, rectum, or other organs or systems of the subject body.
  • the present disclosure comprising the fibrous pack comprising the herbal disinfecting composition was tested on rabbits for investigating toxicity and inflammatory effect.
  • the fibrous packs comprising the herbal disinfecting composition were placed daily and each time for 24 hours in a 14-day course in the vaginas of rabbits of the subject group. Three rabbits were tested as negative-control only with the fibrous pack and without the drug.
  • Fig.4 demonstrates the results of the histology of samples (slides) prepared from the vagina tissue. The results demonstrated that the present herbal disinfecting composition, the object group (Fig.4 images d, e, and f) compared to the control (Fig.4 images a, b, and c) did not cause any significant allergic inflammatory effects in these animals.
  • the herbal disinfecting composition is appropriate to the pH of the environment of the vagina that causes the balance in the environment of the vagina and as a result, prevent the recurrence of the disease and does not disturb the balance of the normal flora of the vagina.
  • the herbal disinfecting composition does not absorb systemically and also since this composition has no or minimum side effects, complications in other organs of the body do not occur.
  • all diseases related to vagina including vaginitis, vaginal discharges, gonorrhea, bacterial vaginosis, sexually transmitted diseases, atrophic vaginitis, fungal infection, genital warts and the like can be treated.
  • composition of the granules and the mentioned properties of the fibrous pack presented in this discloser lead to the controlled drug release.
  • using fibers as drug carriers can play the role of cleaning the environment of the vagina and pelvic organs.
  • using fibers cause the excretion of discharges, infections, residues, remnants, or drug from the environment of the vagina and can cause an effective and high-performance treatment of the vaginal and uterine infections.
  • the herbal disinfecting composition present in the disclosure besides the antibiotic role, have a good potency of penetration in the depth of uterus and pelvic organs and can cause the dissolution of infectious and unnatural discharges in the environment and push the discharges to flow out of the body.
  • the plant species including Citrullus colocynthis, Commiphora myrrha, Myrtus communis, and Rosa damascene, were first obtained and dried.
  • the powder of the fruit of Citrullus colocynthis with a 30-50 wt%, gum of Commiphora myrrha with a 20-50 wt%, leaf of Myrtus communis with a 30-50 wt%, and the bud of Rosa damascene with a 30-50 wt% were mixed.
  • a fibrous pack made from multi-ply (3-6ply) cotton fibers with an annular vertical weave was prepared with a length of 5-10 cm and an area of 2-5 cm as a cone. This pack has a string with an 8-10 cm length in one end that is weaved with the cylindrical body.
  • the powder obtained from mixing the powders of the fruit of Citrullus colocynthis with a 30-50 wt%, gum of Commiphora myrrha with a 20-50 wt%, leaf of Myrtus communis with a 30-50 wt%, and the bud of Rosa damascene with a 30-50 wt% were turned into granules with 1-5 cm sizes.
  • 2-7 g of prepared granules were placed in each fibrous pack.
  • the moisture content of granules, were investigated through two direct and azeotrope methods
  • Fig.4 demonstrates the results of the histology of samples prepared from the vagina tissue. The results demonstrated that the present herbal disinfecting composition, the object group (Fig.4 images d, e, and f) compared to the control (Fig.4 images a, b, and c) did not cause any significant allergic inflammatory effects in these animals.
  • Each complete drug package comprises 14 fibrous packs, and the patient places one daily inside the vagina for a maximum of 24 hours (15-24 hours) and then removes it and uses another pack. To thoroughly treat vaginitis, the patient uses the fibrous packs for 14 days by the said method. In chronic infections or pelvic inflammatory diseases, the treatment can be continued for several courses (6-8 months) until reaching desirable results. Using several courses of this drug caused no or minimum side effects in volunteer patients according to field studies.
  • This fibrous pack was also tested on 30 patients after obtaining their acquiescence for allergy and effectivity tests of the drug. No side effect was reported by the patients. Also, the recovery of patients affected with vaginal infections was confirmed after using one or several treatment courses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention est relative à une composition pharmaceutique comprenant une pluralité de compositions à base d'herbes et le procédé d'administration associé pour prendre soin de la zone vaginale et des organes pelviens de femmes ou servant au traitement de maladies ou de troubles de différents types d'infections associés à ces zones. Ledit procédé comprend l'application d'une quantité efficace d'une composition désinfectante à base d'herbes sur le sujet, la composition désinfectante à base d'herbes comprenant au moins une ou plusieurs plante(s) parmi le genre Citrullus colocynthis, le genre Commiphora myrrha, le genre Myrtus communis genus et le genre Rosa damascene ou un mélange de ces plantes. La composition désinfectante à base d'herbes peut être administrée par l'intermédiaire d'un paquet fibreux à l'intérieur du vagin, le paquet fibreux comprenant un corps cylindrique, un cordon comportant deux extrémités, et une section centrale, la section centrale étant conçue pour contenir la composition désinfectante à base d'herbes.
PCT/IB2020/055399 2019-12-15 2020-06-09 Compositions à base d'herbes et procédés d'administration servant au traitement d'infections et d'inflammation vulvovaginale et des organes pelviens WO2021123925A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE112020006124.8T DE112020006124T5 (de) 2019-12-15 2020-06-09 Pflanzliche Zusammensetzungen und Verabreichungsverfahren zur Behandlung von Infektionen und Entzündungen der vulvovaginalen und der Beckenorgane
CN202080087372.6A CN115066250A (zh) 2019-12-15 2020-06-09 草药化合物和治疗感染、外阴***和盆腔器官炎症的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IR139850140003008438 2019-12-15
IR13983008438 2019-12-15

Publications (1)

Publication Number Publication Date
WO2021123925A1 true WO2021123925A1 (fr) 2021-06-24

Family

ID=83225927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/055399 WO2021123925A1 (fr) 2019-12-15 2020-06-09 Compositions à base d'herbes et procédés d'administration servant au traitement d'infections et d'inflammation vulvovaginale et des organes pelviens

Country Status (3)

Country Link
CN (1) CN115066250A (fr)
DE (1) DE112020006124T5 (fr)
WO (1) WO2021123925A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123539A1 (fr) * 2011-03-17 2012-09-20 Sonia Pharma Gmbh Traitement de l'atrophie vaginale en tant qu'une nouvelle indication de myrrhe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1049480T3 (da) * 1998-01-30 2003-01-27 Rhinopharma As Antiviralt middel af planteoprindelse
JP4249047B2 (ja) * 2004-01-30 2009-04-02 ユニ・チャーム株式会社 生理用タンポン
CN101277661A (zh) * 2005-10-06 2008-10-01 纽约血液中心有限公司 基于邻苯二甲酸乙酸纤维素的抗感染卫生用品
CA2967506A1 (fr) * 2016-01-18 2017-07-18 Nadiah Abdulkarim A. Alessa Composition de traitement et de prevention d'infection, ulcerations et furoncles attribuables au virus du papillome humain (vph)
CN108524622A (zh) * 2018-07-10 2018-09-14 李�杰 一种杀灭***霉菌的卫生棉条

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123539A1 (fr) * 2011-03-17 2012-09-20 Sonia Pharma Gmbh Traitement de l'atrophie vaginale en tant qu'une nouvelle indication de myrrhe

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALSUBHI, WAEL A. ET AL.: "Antifungal Properties of Citrullus colocynthis Leaves Extracts Against Vaginal Candida Infection", ADVANCES IN ENVIRONMENTAL BIOLOGY, vol. 13, no. 2, 25 February 2019 (2019-02-25), pages 1 - 7, XP055834294 *
DATABASE Database 5 August 2013 (2013-08-05), "Ma'joon Maasik-al-baul, Bibliography", XP055836075, Database accession no. AH5/3273 *
DATABASE TKDL 3 March 2010 (2010-03-03), "Farzajah Bekh-e- Indrain", XP055836072, Database accession no. NA2/207AI *
DATABASE TKDL 3 March 2010 (2010-03-03), "Hamool Baraae Badboo-e- Farj", XP055836074, Database accession no. MH2/207T *
NABIMEYBODI R ET AL.: "Scientific Evaluation of Medicinal Plants Used for the Treatment of Cervicitis (Qorohe- Rahem) in Iranian Traditional Medicine", IRAN J PHARM RES., vol. 18, no. 4, 17 October 2019 (2019-10-17), pages 1884 - 1901, XP055834283, DOI: 10.22037/ijpr.2019.1100852 *

Also Published As

Publication number Publication date
DE112020006124T5 (de) 2022-12-08
CN115066250A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
CN110464811A (zh) 一种妇科用泡沫抑菌液及其制备方法
US20130108599A1 (en) Herbal Vaginal Compositions
US20190008905A1 (en) Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases
CN111202822A (zh) 一种妇科外用抗菌喷剂及其制备方法
WO2017101790A1 (fr) Composition pharmaceutique destinée au traitement d'un prurit cutané et son utilisation
CN102697671B (zh) 一种抑菌防病的湿巾药水及其制备方法
CN106176430A (zh) 一种免洗泡沫型女性杀菌液及其制备方法
CN107456509B (zh) 一种用于女性***预防、保健以及治疗妇科生殖道炎症的外用生物制剂以及制备方法
KR20160015718A (ko) 쇠비름 추출물 및 피톤치드를 함유하는 여성 청결제
CN111297794A (zh) 一款调节女性微生态健康的乳酸杆菌妇科凝胶及制备方法
ES2928474T3 (es) Composición natural para uso ginecológico
WO2021123925A1 (fr) Compositions à base d'herbes et procédés d'administration servant au traitement d'infections et d'inflammation vulvovaginale et des organes pelviens
WO2007009185A1 (fr) Miel thérapeutique et son procédé de fabrication
CN108404111A (zh) 一种以芸豆植物凝集素为主要成分的抑菌抗病毒制剂
US5635184A (en) Essential oil composition with bactericide activity
CN111419730A (zh) 一种角鲨烯注氧组合物及其应用
CN106924657A (zh) 一种用于治疗老年性***炎的植物精油组合物及制备方法、应用
CN106267329A (zh) 一种植物精油凝胶敷料及其制备方法和应用
CN105749260B (zh) 一种盐酸溶菌酶***片及其制备方法和应用
AU2007298511B2 (en) Compositions for prevention and treatment of mastitis and metritis
CN101757119B (zh) 一种治疗***炎的药物组合物、凝胶剂及其制备方法
CN112999294A (zh) 一种软凝胶及其制备方法与应用
TR2022014093T2 (tr) Vulvovaji̇nal ve pelvi̇k organlarin enfeksi̇yon ve i̇lti̇haplanmalarinin tedavi̇si̇ne yöneli̇k bi̇tki̇sel bi̇leşi̇kler ve tedavi̇ yöntemleri̇
CN108066278B (zh) 一种含有壳寡糖的妇科用凝胶及其制备方法
KR102413425B1 (ko) 베타글루칸을 포함하는 여성 청결제용 조성물 및 이를 포함하는 진공 충진 앰플

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20903444

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20903444

Country of ref document: EP

Kind code of ref document: A1